The current management strategies for community-acquired urinary tract infection

Infectious Disease Clinics of North America

Volumn 17, Issue 2, 2003, Pages 303-332

  Hooton, Thomas M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFEPIME; CEFIXIME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; FLEROXACIN; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPEMIDIC ACID; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TRIMETHOPRIM;

ACUTE PYELONEPHRITIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIURIA; CHRONIC LUNG DISEASE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; COUGHING; CROSS RESISTANCE; CYSTITIS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DYSPNEA; ENTEROBACTER; ENTEROCOCCUS; EOSINOPHILIA; ESCHERICHIA COLI; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; KLEBSIELLA; MEXICO; MORBIDITY; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PREVALENCE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; THORAX PAIN; TRAVEL; URINARY TRACT INFECTION; URINE CULTURE;

EID: 0037933302     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(03)00004-7     Document Type: Review

References (101)

1. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81.
2. Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997;53:583-92.
3. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90.
4. Ronald AR, Conway B. An approach to urinary tract infections in ambulatory women. Curr Clin Top Infect Dis 1988;9:76-125.
5. Fairley KF, Birch DF. Detection of bladder bacteriuria in patients with acute urinary symptoms. J Infect Dis 1989;159:226-31.
6. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135:9-16.
7. Brumfitt W, Hamilton-Miller JM. A review of the problem of urinary infection management and the evaluation of a potential new antibiotic. J Antimicrob Chemother 1984;13(suppl B):S121-33.
8. Mabeck CE. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad Med J 1972;48:69-75.
9. Asbach HW. Single dose oral administration of cefixime 400 mg in the treatment of acute uncomplicated cystitis and gonorrhoea. Drugs 1991;42(suppl 4):10.
10. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000;46(suppl S1):35-9.
11. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52:708-10.
12. Noskin GA, Zembower T, Chmielewski J, Tang P, La Rosa M, Peterson LR. Disappearance of the "uncomplicated" urinary tract infection: the impact of emerging resistance. Clin Drug Invest 2001;21(suppl 1):13-20.
13. Freedman LR, Andriole VA. The long-term follow-up of women with urinary tract infections. In: Proceedings of the Fifth International Congress on Nephrology (Mexico 1972). Basel: Karger; 1974. p. 3:230.
14. Neu HC. Optimal characteristics of agents to treat uncomplicated urinary tract infection. Infection 1992;20(suppl 4):S266-71.
15. Hooton TM, Running K, Stamm WE. Single dose therapy for cystitis in women: a comparison of trimethoprim-sulfamethoxazole, amoxicillin and cyclacillin. JAMA 1985;253:387-90.
16. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
17. Bergeron MG, Marois Y. Benefit from high intrarenal levels of gentamicin in the treatment of E coli pyelonephritis. Kidney Int 1986;30:481-7.
18. Hooton TM, Stamm WE. The vaginal flora and UTIs. In: Mobley HLT, Warren JW, editors. UTIs: molecular pathogenesis and clinical management. Washington, DC: ASM Press; 1996. p. 67-94.
19. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995;273:41-5.
20. Bent S, Saint S. The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Am J Med 2002;113:20S-8S.
21. Rubin UH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 1992;15:S216-27.
22. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135:41-50.
23. Gupta K. Addressing antibiotic resistance. Am J Med 2002;113:29S-34S.
24. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002;287:2701-10.
25. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001;33:89-94.
26. Kahlmeter G. The ECO-SENS project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000;46(suppl 1):15-22.
27. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infection caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001;345:1007-13.
28. Johnson JR, O'Bryan TT, Manges AR, Riley LW. Emergence of a multi-drug resistant clonal group of extraintestinal pathogenic Escherichia coli as a significant cause of acute pyelonephritis [abstract 853]. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 25-28, 2001.
29. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-5.
30. Zhanel GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:324-6.
31. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281:736-8.
32. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002;34:1061-6.
33. Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995;35:129-37.
34. McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999;106:292-9.
35. Raz R, Chazan B, Kennes Y, Colodner R, Rollensterich E, Dan M, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34:1165-9.
36. Nicolle LE, Hoepelman AI, Floor M, Verhoef J, Norgard K. Comparison of three days therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. Scand J Infect Dis 1993;25:631-7.
37. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999;14:606-9.
38. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J Antimicrob Chemother 1999;43:841-3.
39. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001;47:781-7.
40. Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine MH. Exposure to co-amxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 2002;49:367-71.
41. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
42. McGowan JE Jr., Chesney PJ, Crossley KB, LaForce FM. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J Infect Dis 1992;165:1-13.
43. Leibovici L, Wysenbeek AJ. Single-dose antibiotic treatment for symptomatic urinary tract infections in women: a meta-analysis of randomized trials. Q J Med 1991;78:43-57.
44. Sigurdsson JA, Ahlmen J, Berglund L, et al. Three-day treatment of acute lower urinary tract infections in women: a double-blind study with amoxicillin and co-trimazine. Acta Med Scand 1983;213:55-60.
45. Swedish Urinary Tract Infection Group. Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Clin Infect Dis 1995;20:507-13.
46. Bailey RR. Continuing problems with the use of Augmentin for urinary tract infections. N Z Med J 1995;108:465.
47. Raz R, Rottensterich E, Boger S, Potasman I. Comparison of single-dose administration and three-day course of amoxicillin with those of clavulanic acid for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 1991;35:1688-90.
48. Iravani A, Richard GA, Johnson D, Bryant A. A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients. Am J Med 1988;85:17-23.
49. Cox CE. Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections. Urology 1989;34:322-6.
50. Raz R, Rottensterich E, Leshem Y, Tabenkin H. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother 1994;38:1176-7.
51. Giamarellou H. Oral cephalosporins: clinical results in urinary tract infections. In: Moellering RC Jr, editor. Oral cephalosporins. Antibiot Chemother 1995;47:145-59.
52. Cox CE, Graveline JF, Luongo JM. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infection. Drugs 1991;42:41.
53. Goto T, Kitagawa T, Kawahara M, Hayami H, Ohi Y. Comparative study of single-dose and three-day therapy for acute uncomplicated cystitis. Hinyokika Kiyo 1999;45:85-9.
54. Furusawa T, Hiratake Y, Mishina T, et al. Evaluation of clinical efficacy and safety of cefpodoxime proxetil (CPDX-PR) in acute uncomplicated cystitis. Hinyokika Kiyo 1994;40:853-60.
55. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002;113:35S-44S.
56. Cunha BA. Nitrofurantoin: an update. Obstet Gynecol Surv 1989;44:399-406.
57. Gossius G. Single-dose nitrofurantoin therapy for urinary tract infections in women. Curr Ther Res 1984;35:925.
58. Pelletier LL, Michalak DP, Carter JZ, et al. A comparison of Macrobid (nitrofurantoin monohydrate/macrocrystals) and Macrodantin (nitrofurantoin macrocrystals) in the treatment of acute episodes of uncomplicated lower urinary tract infection. Adv Ther 1992;9:32.
59. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother 1994;33(suppl A):121-9.
60. McOsker CC, Pollack JR, Andersen JA. Inhibition of bacterial protein synthesis by nitrofurantoin macrocrystals: an explanation for the continued efficacy of nitrofurantoin. In: Harrison LH, editor. Management of urinary tract infection, Royal Society of Medicine Services International Congress and Symposium Series. No. 154. London: Royal Society of Medicine; 1990. p. 33-44.
61. Physicians' desk reference. Montvale, NJ: Medical Economics Company; 2002.
62. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43(suppl A):67-75.
63. Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001;61:353-64.
64. Brumfitt W, Hamilton-Miller JMT. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. J Antimicrob Chemother 1998;42:363-71.
65. Hallas J, Gram LF, Grodum E, et al. Drug-related admissions to medical wards: a population-based survey. Br J Clin Pharmacol 1992;33:61-8.
66. Bailey RR. Quinolones in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 1992;2:19.
67. Andriole VT. Use of quinolones in treatment of prostatitis and lower urinary tract infections. Eur J Clin Microbiol Infect Dis 1991;10:342.
68. Iravani A, Tice AD, McCarty J, Sikes DA, Nolen T, Gallis HA, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. Arch Intern Med 1995;155:485-94.
69. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002;59:334-9.
70. Richard GA, DeAbate CA, Ruoff GE, Corrado M, Fowler CL, Morgan N. A double-blind, randomized trial of the efficacy and safety of short-course, once-daily levofloxacin versus ofloxacin twice daily in uncomplicated urinary tract infection. Infect Dis Clin Practice 1998;9:323-9.
71. Inter-Nordic Urinary Tract Infection Study Group. Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. Scand J Infect Dis 1988;20:619.
72. Hooton TM, Johnson C, Winter C, Kuwamura L, Rogers ME, Roberts PL, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agent Chemother 1991;35:1479-83.
73. Henry D, Ellison W, Sullivan J, Mansfield DL, Magner DJ, Dorr MB, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother 1998;42:2262-6.
74. Ball P. Bacterial resistance to fluoroquinolones: lessons to be learned. Infection 1994;22(suppl 2):S140-7.
75. Boerema JBJ, Willems FTC. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990;18(suppl 2):S80-8.
76. De Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991;46:344-8.
77. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999;21:1864-72.
78. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single dose fosfomycin trometamol (monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998;10:9-47.
79. Naber KG, Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection 1990;18:S70-6.
80. Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection 1990;18(suppl 2):S89-93.
81. Fosfomycin for urinary tract infections. Med Lett 1997;39:66-8.
82. Leibovici L. Antibiotic treatment for cystitis. Br J Gen Pract 2002;52:708-10.
83. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infection. Int J Antimicrob Agents 1999;11:247-51.
84. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis 2001;33:615-21.
85. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother 2000;46(suppl A):49-52.
86. Safrin S, Siegel D, Black D. Pyelonephritis in adult women: inpatient versus outpatient therapy. Am J Med 1988;85:793-8.
87. Plumridge RJ, Golledge CL. Treatment of urinary tract infection: clinical and economic considerations. Pharmacoeconomics 1996;9:295.
88. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987;106:341-5.
89. Stamey TA. Recurrent urinary tract infections in female patients: An overview of management and treatment. Rev Infect Dis 1987;9(suppl 2):S195-210.
90. Jernelius H, Zbornik J, Bauer C. One or three week treatment of acute pyelonephritis: a double-blind comparison using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988;223:469.
91. Ode B, Broms M, Walder M, Cronberg S. Failure of excessive doses of ampicillin to prevent bacterial relapse in the treatment of acute pyelonephritis. Acta Med Scand 1980;207:305-7.
92. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
93. Bergeron MG. Treatment of pyelonephritis in adults. Med Clin North Am 1995;79:619-49.
94. Caceres VM, Stange KC, Kikano GE, et al. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis. J Fam Pract 1994;39:337-9.
95. Papanicolaou N, Pfister RC. Acute renal infections. Radiol Clin North Am 1996;34:965-95.
96. Boam WD, Miser WF. Acute focal bacterial pyelonephritis. Am Fam Phys 1995;52:919-24.
97. Wyatt SH, Urban BA, Fishman EK. Spiral CT of the kidneys: role in characterization of renal disease. Part I: nonneoplastic disease. Crit Rev Diagn Imaging 1995;36:1-37.
98. Raz R, Rozenfeld S. 3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women. Antimicrob Agents Chemother 1996;40:2200-1.
99. Schultz HJ, McCaffrey LA, Keys TF, Nobrega FT. Acute cystitis: a prospective study of laboratory tests and duration of therapy. Mayo Clin Proc 1984;59:391-7.
100. Zhanel GG, Harding GKM, Guay DRP. Asymptomatic bacteriuria: which patients should be treated? Arch Intern Med 1990;150:1389-96.
101. Khan AJ, Schaeffer HA, Evans H. Urinary tract infection in adolescent boys. J Natl Med Assoc 1996;88:25-6.